Women are still underrepresented in heart drug trials

On average, only 34% of participants are female

Pivotal clinical trials that are used to win US marketing approval for many new heart drugs don't include enough women to clearly assess gender differences, a recent study suggests.

gender differences

This is because fewer women than men are invited to participate.

Over the study period, the mean percentage of women participants was 34% (ranging from 22% to 81%) across different cardiovascular areas.

This is problematic, say the authors, because there are sex and gender differences in how heart disease impacts the body, symptoms and treatment outcomes.

Latest

Trending